TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general conditions and comorbidities, treatments’ objectives, and dise...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Cremolini, Chiara, Marmorino, Federica, Loupakis, Fotios, Masi, Gianluca, Antoniotti, Carlotta, Salvatore, Lisa, Schirripa, Marta, Boni, Luca, Zagonel, Vittorina, Lonardi, Sara, Aprile, Giuseppe, Tamburini, Emiliano, Ricci, Vincenzo, Ronzoni, Monica, Pietrantonio, Filippo, Valsuani, Chiara, Tomasello, Gianluca, Passardi, Alessandro, Allegrini, Giacomo, Di Donato, Samantha, Santini, Daniele, Falcone, Alfredo
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466800/
https://ncbi.nlm.nih.gov/pubmed/28599628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3360-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados